An International Survey Investigating the Incidence and Management of Brown Fat Uptake on18F-FDG PET/CT at Children’s Hospitals and Interventions for Mitigation
William C. Gaylord, Andrew T. Trout, Anthony N. Audino, Jennifer A. Belsky
{"title":"An International Survey Investigating the Incidence and Management of Brown Fat Uptake on18F-FDG PET/CT at Children’s Hospitals and Interventions for Mitigation","authors":"William C. Gaylord, Andrew T. Trout, Anthony N. Audino, Jennifer A. Belsky","doi":"10.2967/jnmt.123.266536","DOIUrl":null,"url":null,"abstract":"Brown fat can present challenges in patients with cancer who undergo 18 F-FDG PET scans. Uptake of 18 F-FDG by brown fat can obscure or appear similar to active oncologic lesions, causing clinical challenges in PET interpretation. Small, retrospective studies have reported environmental and pharmacologic interventions for suppressing brown fat uptake on PET; however, there is no clear consensus on best practices. We sought to characterize practice patterns for strategies to mitigate brown fat uptake of 18 F-FDG during PET scanning. Methods: A survey was developed and distributed via e-mail LISTSERV to members of the Children ’ s Oncology Group diagnostic imaging committee, the Society for Nuclear Medicine and Molecular Imaging pediatric imaging council, and the Society of Chiefs of Radiology at Children ’ s Hospitals between April 2022 and February 2023. Responses were stored anony-mously in REDCap, aggregated, and summarized using descriptive statistics. Results: Fifty-fi ve complete responses were submitted: 51 (93%) faculty and fellow-level physicians, 2 (4%) technologists, and 2 (4%) respondents not reporting their rank. There were 43 unique institutions represented, including 5 (12%) outside the United States. Thirty-eight of 41 (93%) institutions that responded on environmental interventions reported using warm blankets in the infusion and scanning rooms. Less than a third ( n 5 13, 30%) of institutions reported use of a pharmacologic intervention, with propranolol ( n 5 5, 38%) being most common, followed by fentanyl ( n 5 4, 31%), diazepam ( n 5 2, 15%), and diazepam plus pro-pranolol ( n 5 2, 15%). Selection criteria for pharmacologic intervention varied, with the most common criterion being brown fat uptake on a prior scan ( n 5 6, 45%). Conclusion: Clinical practices to mitigate brown fat uptake on pediatric 18 F-FDG PET vary widely. Simple environmental interventions including warm blan-kets or increasing the temperature of the injection and scanning rooms were not universally reported. Less than a third of institutions use pharmacologic agents for brown fat mitigation.","PeriodicalId":16548,"journal":{"name":"Journal of nuclear medicine technology","volume":null,"pages":null},"PeriodicalIF":1.0000,"publicationDate":"2023-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of nuclear medicine technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2967/jnmt.123.266536","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
Abstract
Brown fat can present challenges in patients with cancer who undergo 18 F-FDG PET scans. Uptake of 18 F-FDG by brown fat can obscure or appear similar to active oncologic lesions, causing clinical challenges in PET interpretation. Small, retrospective studies have reported environmental and pharmacologic interventions for suppressing brown fat uptake on PET; however, there is no clear consensus on best practices. We sought to characterize practice patterns for strategies to mitigate brown fat uptake of 18 F-FDG during PET scanning. Methods: A survey was developed and distributed via e-mail LISTSERV to members of the Children ’ s Oncology Group diagnostic imaging committee, the Society for Nuclear Medicine and Molecular Imaging pediatric imaging council, and the Society of Chiefs of Radiology at Children ’ s Hospitals between April 2022 and February 2023. Responses were stored anony-mously in REDCap, aggregated, and summarized using descriptive statistics. Results: Fifty-fi ve complete responses were submitted: 51 (93%) faculty and fellow-level physicians, 2 (4%) technologists, and 2 (4%) respondents not reporting their rank. There were 43 unique institutions represented, including 5 (12%) outside the United States. Thirty-eight of 41 (93%) institutions that responded on environmental interventions reported using warm blankets in the infusion and scanning rooms. Less than a third ( n 5 13, 30%) of institutions reported use of a pharmacologic intervention, with propranolol ( n 5 5, 38%) being most common, followed by fentanyl ( n 5 4, 31%), diazepam ( n 5 2, 15%), and diazepam plus pro-pranolol ( n 5 2, 15%). Selection criteria for pharmacologic intervention varied, with the most common criterion being brown fat uptake on a prior scan ( n 5 6, 45%). Conclusion: Clinical practices to mitigate brown fat uptake on pediatric 18 F-FDG PET vary widely. Simple environmental interventions including warm blan-kets or increasing the temperature of the injection and scanning rooms were not universally reported. Less than a third of institutions use pharmacologic agents for brown fat mitigation.